| Line Item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues, net | ||||||||||||||||
| YoY growth | +2135.6% | -33.5% | -66.7% | -77.8% | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Research and development (includes $7,965 and $10,996 of share-based compensation expense for the three months ended September 30, 2026 and 2025 and $16,686 and $22,095 for the six months ended September 30, 2026 and September 30, 2025, respectively) | ||||||||||||||||
| Selling, general and administrative (includes $71,332 and $70,825 of share-based compensation expense for the three months ended September 30, 2026 and 2025 and $145,953 and $141,904 for the six months ended September 30, 2026 and 2025, respectively) | — | — | — | |||||||||||||
| Total operating expenses | ||||||||||||||||
| % of revenue | 863.2% | 25508.1% | 14187.1% | 17066.1% | ||||||||||||
| Gain on litigation settlement | — | — | ||||||||||||||
| Loss from operations | ||||||||||||||||
| % of revenue | -763.2% | -25380.9% | 16477.8% | -16966.1% | ||||||||||||
| Change in fair value of investments | ||||||||||||||||
| Change in fair value of liability instruments | ||||||||||||||||
| Interest income | ||||||||||||||||
| Other expense, net | ||||||||||||||||
| Loss from continuing operations before income taxes | ||||||||||||||||
| Income tax (benefit) expense | ||||||||||||||||
| Loss from continuing operations, net of tax | — | |||||||||||||||
| Income from discontinued operations, net of tax | — | |||||||||||||||
| Net loss | ||||||||||||||||
| % of revenue | -390.7% | -20153.0% | 14116.8% | -15692.9% | ||||||||||||
| Net income (loss) attributable to noncontrolling interests | ||||||||||||||||
| Net loss attributable to Roivant Sciences Ltd. | ||||||||||||||||
| % of revenue | -545.6% | -13164.8% | 12023.6% | -13301.2% | ||||||||||||
| Amounts attributable to Roivant Sciences Ltd.: | ||||||||||||||||
| Net loss attributable to Roivant Sciences Ltd. | — | — | — | |||||||||||||
| % of revenue | -545.6% | — | — | — | ||||||||||||
| Net loss per common share—basic (in dollars per share) | ||||||||||||||||
| Net loss per common share— diluted (in dollars per share) |